[CES 2025 Seoul Integrated Pavilion] Neudive 'Buddy-in' – Opening a New Chapter for Neurodivergent Individuals and Their Families Through Digital Health Innovation
- Jul 6
- 3 min read
CES 2025 Innovation Award WinnerNeudive 'Buddy-in' – Opening a New Chapter for Neurodivergent Individuals and Their Families Through Digital Health Innovation
Neudive Co., Ltd. (CEO Sung-ja Cho) unveiled 'Buddy-in' at the CES 2025 Seoul Integrated Pavilion and received the Innovation Award in the Digital Health category. A member of Seoul BioHub, Neudive is a health-tech company dedicated to providing accessible therapeutic solutions for neurodivergent individuals — including those with Autism Spectrum Disorder (ASD) and Social Communication Disorder — and their families.
◇ 'Buddy-in': Easy Social Skills Training at Home
Buddy-in, developed by Neudive, is a digital therapeutic software for children and adolescents with Autism Spectrum Disorder and Social Communication Disorder. Conventional face-to-face therapy has long placed a burden on many families due to a shortage of therapists and high costs. Buddy-in addresses these challenges, enabling users to easily engage in social skills training from home.
Designed as an AI-based software, the product analyzes users' interaction data to deliver personalized learning content, and creates an environment where children and parents can participate together through an engaging and intuitive interface.
Safety and efficacy were statistically confirmed in an exploratory clinical trial conducted at three domestic university hospitals in 2023, and the results were presented at prestigious academic conferences including the Korean Neuropsychiatric Association and the American Academy of Child and Adolescent Psychiatry. Neudive has also obtained GMP certification from the Ministry of Food and Drug Safety, officially recognizing the quality of Buddy-in as a digital therapeutic device.
◇ Global Competitiveness Proven by the CES 2025 Innovation Award
Having won the Innovation Award in the Digital Health category at CES 2025, Buddy-in was also featured at the Unveiled event, drawing significant attention from overseas buyers and investors. As no digital therapeutic device for Autism Spectrum Disorder has yet received FDA or MFDS approval anywhere in the world, Neudive is aiming to make Buddy-in a global market breakthrough.
CEO Sung-ja Cho stated: "We are focused on expanding access to treatment and improving the quality of life for neurodivergent individuals and their families around the world. We will showcase our technological capabilities at CES and lay the groundwork for entering the global market."
◇ Developing Additional Solutions for Diverse Neurodivergent Needs
Beyond Buddy-in, Neudive is developing several other innovative products. 'BuddyPlan,' for which a Japanese-language validation study is currently underway, is a social skills assessment tool that scientifically measures the level of social skills in neurodivergent individuals. In addition, 'BuddyStep,' an executive function training program for children with ADHD and Autism Spectrum Disorder, helps improve adaptive abilities.
These products are expected to enhance treatment accessibility and reduce financial burdens for patients and families in areas with a shortage of treatment facilities, while also complementing the existing healthcare system.
◇ Presenting the Future of Digital Health
At Neudive's booth, CES 2025 attendees can experience a live demo, offering the opportunity to directly experience the therapeutic journey of neurodivergent users through Buddy-in. Through this exhibition, Neudive is strengthening collaboration with overseas partners and attracting investment in preparation for a full-scale leap into the global market.
Neudive's innovation is dramatically improving access to treatment for neurodivergent conditions such as Autism Spectrum Disorder and opening new possibilities in digital health. With the momentum of the CES 2025 Innovation Award, Neudive's growth in the global health-tech market is highly anticipated.
The CES 2025 Seoul Integrated Pavilion features the largest-ever participation, with 104 startups from a total of 16 partner organizations, including 3 autonomous districts (Gangnam, Geumcheon, and Gwanak), 5 startup support agencies (SBA, Seoul Tourism Foundation, Seoul BioHub, Seoul AI Hub, and Campus Town Growth Center), and 8 universities (Konkuk University, Kyung Hee University, Kookmin University, Dongguk University, Sogang University, University of Seoul, Yonsei University, and Chung-Ang University).
Source: StartupN (https://www.startupn.kr)
